Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Alvotech and Advanz Pharma expand their European biosimilar partnership to include AVT10, targeting Cimzia® for rheumatic ...

We came across a bullish thesis on Alvotech (ALVO) on M.V Cunha’s Substack. In this article, we will summarize the bulls’ ...

In accordance with the Remuneration Policy of Alvotech (the “Company”), which was approved at the Company’s Annual General ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Potential Positives. Alvotech received a positive opinion from the EMA's CHMP, bringing the proposed biosimilar AVT06 closer to market approval in the European Economic Area.

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Merck Sharp & Dohme’s Keytruda (pembrolizumab) ...

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million.

REYKJAVIK, ICELAND and LONDON, UK— Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco ...

Alvotech & Advanz Pharma ink European supply and commercialization agreement for biosimilar candidate to Cimzia: Reykjavik, Iceland Wednesday, July 2, 2025, 09:00 Hrs [IST] Alvote ...

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol) ...